Functional and bioenergetic consequences of AT1 antagonist olmesartan medoxomil in hearts with postinfarction LV remodeling.
The structural left ventricular (LV) remodeling and contractile dysfunction of hearts with postinfarction LV remodeling are benefited by angiotensin II type 1 receptor (AT1) blocker. However, the myocardial bioenergetic consequences of AT1 blocker in these hearts are not known. To investigate, we used a porcine model of postinfarction LV remodeling produced by ligation of the left circumflex coronary artery. After infarction, 7 pigs received olmesartan medoxomil (2 mg/kg) for comparison against 9 untreated and 10 normal pigs. Measurements of hemodynamics, myocardial perfusion, and myocardial bioenergetics were taken 7 weeks postinfarction. The treated group had an LV-to-body weight ratio significantly lower than the untreated group (2.69 +/- 0.70, 2.96 +/- 0.51, 3.66 +/- 0.60 g/kg for control, treated, and untreated groups, respectively). The untreated group had a mean aortic pressure significantly higher than the control (73 +/- 16, 86 +/- 14, and 94 +/- 20 mm Hg, respectively). The subendocardial phosphocreatine-to-ATP ratios of the treated group were significantly higher than that of the untreated group. The untreated group, but not the treated group, had significant reductions in mitochondrial F0F1-ATPase subunits compared with controls. Congestive heart failure as evidenced by significant ascites (100 to 2000 mL) developed in 4 of the 9 untreated animals, but was absent in the treated group. Animals with heart failure demonstrated reductions in both mitochondrial F0F1-ATPase expression and myocardial high-energy phosphate levels. Thus, severe LV dysfunction and accompanying abnormal myocardial bioenergetic phenotype were prevented by the AT1 antagonist olmesartan medoxomil.
Ochiai
Koichi
K
Department of Medicine, University of Minnesota Health Sciences, Minneapolis, MN 55455, USA.
Hu
Qingsong
Q
Lee
Joseph
J
Mansoor
Abdul
A
Liu
Jingbo
J
Wang
Xiaohong
X
Gong
Guangrong
G
Murakami
Yo
Y
Ishibashi
Yukada
Y
Shimada
Toshio
T
Zhang
Jianyi
J
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000818:Animals; D003331:Coronary Vessels; D004734:Energy Metabolism; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006333:Heart Failure / Q000517:prevention & control*; D007093:Imidazoles / Q000494:pharmacology*; D009682:Magnetic Resonance Spectroscopy; D008928:Mitochondria / Q000201:enzymology; D009203:Myocardial Infarction / Q000378:metabolism / Q000503:physiopathology*; D000068557:Olmesartan Medoxomil; D010101:Oxygen Consumption; D010710:Phosphates / Q000378:metabolism; D006180:Proton-Translocating ATPases / Q000032:analysis; D012084:Renin-Angiotensin System / Q000187:drug effects; D013552:Swine; D013777:Tetrazoles / Q000494:pharmacology*; D020257:Ventricular Remodeling / Q000187:drug effects*
D047228:Angiotensin II Type 1 Receptor Blockers; D007093:Imidazoles; D010710:Phosphates; D013777:Tetrazoles; D000068557:Olmesartan Medoxomil; D006180:Proton-Translocating ATPases